{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T04:41:46Z","timestamp":1786250506535,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04527-x","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:42:11Z","timestamp":1786203731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term results of preoperative hypofractionated chemoradiotherapy for high-risk HER2-positive and triple-negative breast cancer subtypes"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0130-878X","authenticated-orcid":false,"given":"Raquel","family":"Ci\u00e9rvide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Garc\u00eda-Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"5","key":"4527_CR1","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1245\/s10434-015-4406-6","volume":"22","author":"EP Mamounas","year":"2015","unstructured":"Mamounas EP. Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol. 2015;22(5):1425\u201333. https:\/\/doi.org\/10.1245\/s10434-015-4406-6.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"4527_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ejso.2017.02.002","volume":"43","author":"M Teshome","year":"2017","unstructured":"Teshome M, Kuerer HM. Breast conserving surgery and locoregional control after neoadjuvant chemotherapy. Eur J Surg Oncol. 2017;43(5):865\u201374. https:\/\/doi.org\/10.1016\/j.ejso.2017.02.002.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"4527_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/med.21998","volume":"44","author":"X Kong","year":"2024","unstructured":"Kong X, Song J, Gao P, Gao R, Zhang L, Fang Y, et al. Revolutionizing the battle against locally advanced breast cancer: a comprehensive insight into neoadjuvant radiotherapy. Med Res Rev. 2024;44(2):606\u201331. https:\/\/doi.org\/10.1002\/med.21998.","journal-title":"Med Res Rev"},{"issue":"3","key":"4527_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.semradonc.2022.01.003","volume":"32","author":"L Singer","year":"2022","unstructured":"Singer L, Weiss A, Bellon JR, King TA. Regional nodal management after preoperative systemic therapy. Semin Radiat Oncol. 2022;32(3):228\u201336. https:\/\/doi.org\/10.1016\/j.semradonc.2022.01.003.","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"4527_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/GCO.0000000000000672","volume":"33","author":"M Untch","year":"2021","unstructured":"Untch M. Local and regional therapy considerations after preoperative therapy in patients with breast cancer. Curr Opin Obstet Gynecol. 2021;33(1):59\u201363. https:\/\/doi.org\/10.1097\/GCO.0000000000000672.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"9938","key":"4527_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer\u202f: the CTNeoBC pooled analysis. The Lancet. 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"The Lancet"},{"key":"4527_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2025.111236","volume":"214","author":"A Zamagni","year":"2026","unstructured":"Zamagni A, Luis AM, Mjaaland I, Chirila ME, Ciervide R, Machiels M, et al. ESTRO recommendations on preoperative radiation therapy in breast cancer: current and future perspectives-endorsed by ASTRO. Radiotherapy Oncol. 2026;214:1\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2025.111236.","journal-title":"Radiotherapy Oncol."},{"key":"4527_CR8","first-page":"3","volume":"9","author":"R Ciervide","year":"2019","unstructured":"Ciervide R, Montero A, Garcia-Aranda M, Vega E, Herrero M, Ramirez N, et al. Neoadjuvant chemoradiation for unfavourable breast cancer patients: a prospective cohort study. J Clin Trials. 2019;9:3.","journal-title":"J Clin Trials"},{"key":"4527_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184531","author":"R Ci\u00e9rvide","year":"2022","unstructured":"Ci\u00e9rvide R, Montero \u00c1, Garc\u00eda-Rico E, Garc\u00eda-Aranda M, Herrero M, Skaarup J, et al. Primary chemoradiotherapy treatment (PCRT) for HER2+ and triple negative breast cancer patients: a feasible combination. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14184531.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4527_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","volume":"114","author":"BV Offersen","year":"2015","unstructured":"Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015;114(1):3\u201310. https:\/\/doi.org\/10.1016\/j.radonc.2014.11.030.","journal-title":"Radiother Oncol"},{"issue":"5","key":"4527_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/s0960-9776(03)00106-1","volume":"12","author":"KN Ogston","year":"2003","unstructured":"Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320\u20137. https:\/\/doi.org\/10.1016\/s0960-9776(03)00106-1.","journal-title":"Breast"},{"issue":"2","key":"4527_CR12","first-page":"133","volume":"14","author":"NK Aaronson","year":"1988","unstructured":"Aaronson NK, Bartelink H, van Dongen JA, van Dam FS. Evaluation of breast conserving therapy: clinical, methodological and psychosocial perspectives. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 1988;14(2):133\u201340.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"2","key":"4527_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0360-3016(79)90729-6","volume":"5","author":"JR Harris","year":"1979","unstructured":"Harris JR, Levene MB, Svensson G, Hellman S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1979;5(2):257\u201361. https:\/\/doi.org\/10.1016\/0360-3016(79)90729-6.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4527_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2025.102191","volume":"60","author":"D Ga\u0161par","year":"2025","unstructured":"Ga\u0161par D, Taka\u010d I, Sobo\u010dan M. Current approaches to breast reconstruction: a scoping review of outcomes and factors influencing core outcome sets. Surg Oncol. 2025;60:102191. https:\/\/doi.org\/10.1016\/j.suronc.2025.102191.","journal-title":"Surg Oncol"},{"issue":"10","key":"4527_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamasurg.2018.1677","volume":"153","author":"KB Santosa","year":"2018","unstructured":"Santosa KB, Qi J, Kim HM, Hamill JB, Wilkins EG, Pusic AL. Long-term patient-reported outcomes in postmastectomy breast reconstruction. JAMA Surg. 2018;153(10):891\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2018.1677.","journal-title":"JAMA Surg"},{"issue":"10","key":"4527_CR16","doi-asserted-by":"publisher","first-page":"CD013821","DOI":"10.1002\/14651858.CD013821.pub2","volume":"10","author":"N Rocco","year":"2024","unstructured":"Rocco N, Catanuto GF, Accardo G, Velotti N, Chiodini P, Cinquini M, et al. Implants versus autologous tissue flaps for breast reconstruction following mastectomy. Cochrane Database Syst Rev. 2024;10(10):CD013821. https:\/\/doi.org\/10.1002\/14651858.CD013821.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"4527_CR17","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/S1470-2045(14)71104-0","volume":"16","author":"MS Moran","year":"2015","unstructured":"Moran MS. Radiation therapy in the locoregional treatment of triple-negative breast cancer. Lancet Oncol. 2015;16(3):e113\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(14)71104-0.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4527_CR18","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamasurg.2025.2324","volume":"160","author":"LS Dominici","year":"2025","unstructured":"Dominici LS, Zheng Y, King TA, Wong J, Ruddy KJ, Tamimi RM, et al. Long-term locoregional outcomes in a contemporary cohort of young women with breast cancer. JAMA Surg. 2025;160(9):964\u201371. https:\/\/doi.org\/10.1001\/jamasurg.2025.2324.","journal-title":"JAMA Surg"},{"issue":"1","key":"4527_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/bjc.2017.379","volume":"118","author":"SM Reddy","year":"2018","unstructured":"Reddy SM, Barcenas CH, Sinha AK, Hsu L, Moulder SL, Tripathy D, et al. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer. 2018;118(1):17\u201323. https:\/\/doi.org\/10.1038\/bjc.2017.379.","journal-title":"Br J Cancer"},{"key":"4527_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.617593","volume":"10","author":"N Xie","year":"2020","unstructured":"Xie N, Xu Y, Zhong Y, Li J, Yao H, Qin T. Clinicopathological characteristics and treatment strategies of triple-negative breast cancer patients with a survival longer than 5 years. Front Oncol. 2020;10:617593. https:\/\/doi.org\/10.3389\/fonc.2020.617593.","journal-title":"Front Oncol"},{"issue":"21","key":"4527_CR21","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391(21):1981\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2409932.","journal-title":"N Engl J Med"},{"issue":"1","key":"4527_CR22","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1038\/s41598-023-38200-y","volume":"13","author":"Y-J Kang","year":"2023","unstructured":"Kang Y-J, Oh SJ, Bae SY, Kim E-K, Lee Y-J, Park EH, et al. Predictive biological factors for late survival in patients with HER2-positive breast cancer. Sci Rep. 2023;13(1):11008. https:\/\/doi.org\/10.1038\/s41598-023-38200-y.","journal-title":"Sci Rep"},{"issue":"16","key":"4527_CR23","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1200\/JCO.22.02241","volume":"41","author":"MT van Mackelenbergh","year":"2023","unstructured":"van Mackelenbergh MT, Loibl S, Untch M, Buyse M, Geyer CEJ, Gianni L, et al. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(16):2998\u20133008. https:\/\/doi.org\/10.1200\/JCO.22.02241.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9938","key":"4527_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet"},{"key":"4527_CR25","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-18028-8","author":"V Huynh","year":"2025","unstructured":"Huynh V, Glencer A, Yi M, Wingate E, Wingate H, Allassan N, et al. Impact of pathologic complete response on local-regional recurrence and survival in patients undergoing neoadjuvant systemic therapy and breast-conserving surgery. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-18028-8.","journal-title":"Ann Surg Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04527-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04527-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04527-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T04:01:34Z","timestamp":1786248094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04527-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":25,"alternative-id":["4527"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04527-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the authors declare no conflict of interest regarding any aspect related to this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional research committee and with the Helsinki declaration and informed consent was obtained from all individuals participants included in this study.","order":2,"name":"Ethics","label":"Ethical approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the author(s) used chatGPT40 for graphical abstract design. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for its content.","order":3,"name":"Ethics","label":"Use of AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}}]}}